Gelexir Healthcare raises £414k to advance clinical studies for its back pain treatment

Gelexir Healthcare has secured £414k in the first close of its current £950k funding round, supported by the Co Angel Investment service. The capital will enable the medical technology firm to advance through pre-clinical trials and progress toward initial human clinical studies. Participants in the financing include The North West Fund for Biomedical, Central Manchester Foundation Trust, and various angel investors.

The company is developing a novel hydrogel treatment intended to restore normal disk function and eliminate the necessity for invasive spinal surgery. This fresh injection of capital marks a key milestone for the Manchester-based business as it prepares for broader clinical evaluation. The broader funding initiative continues with ongoing assistance from the Greater Manchester-backed platform.